ADME | Biologics | Cancer metabolism | Cellular signalling | DMPK | Drug development | Drug repositioning | ECM | GPCR | Ion channel | Kinase | Kinetics | Lead optimisation | Lead discovery | Monoclonal | Natural products | Rational drug design | Target validation | Toxicity | Ubiquitination | Zebrafish |
Pharma Derisking approaches to reduce liability to major metabolically-driven causes of drug attrition By Guy Webber Spring 2017
Intelligent application of early in vitro testing can help mitigate major drug development risks.
Three-dimensional cell culture: a rapidly emerging technique for drug discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen Spring 2017
The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.
A strategic vision for 21st Century drug discovery. By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Winter 16/17
Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the aetiology of diseases, it is generally accepted that the current approach to creating new small molecule therapeutics remains fundamentally inefficient.
Kinases and drug discovery: protein kinases as a validated drug target. By Professor Said A. Goueli Winter 16/17
The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. The payoff for the pharmaceutical industries has been substantial.
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu Winter 16/17
As yesterdayâs lead molecule enters todayâs clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating basic scientists, lest their lofty impractical ideals disrupt a delicate balance of strategic compromise. Indeed many scientists may not understand the competing push and pull of efficacy versus toxicity and quality versus production costs.
Ion Channels - increasingly enticing targets for drug discovery. by Dr Douglas Krafte and Deborah Erickson Summer 2016
Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease.
Reigniting pharmaceutical innovation through holistic drug targeting By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Summer 2016
Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.
Drug Discovery in a Multi-Omics World By Mike Furness Winter 2015/16
Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development.
Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis. By David M. Kauppi and Dr Stephen Naylor Winter 2015/16
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector.
When two are not enough: lead optimisation beyond matched pairs. By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall Fall 2015
Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure where the goal is not only to improve potency but also to improve physicochemical and ADME properties.
The increasing impact of precision research models on drug discovery and development. Dr Amar Thyagarajan Fall 2015
Animal models are the standard by which we gain insight into the complex biological processes that underlie normal human physiology and disease states. Rodent models such as rats and mice have been used to understand various aspects of human physiology, disease and treatment outcomes.
How neutron science has enabled innovation in drug design and delivery. By Dr Giovanna Fragneto Fall 2015
Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes â not just at the level of cells but right down at the molecular level. And designing the most efficient therapeutics requires an in-depth understanding of the disease.
Ultra-sensitive measurement of protein and nucleic acid biomarkers may enable earlier disease detection and more effective therapies : Winter 06 By Dr Gregory Shipp Winter 2006
The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious and genetic conditions, and is placing emphasis on treatments related to the early detection of disease.
Neutron scattering provides unique insights for drug R&D. Fall 10 By Dr Martyn Bull Fall 2010
Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically.
Page 1 to 14 of 53 | NEXT PAGE >